Before Anyone Pours: CBD and an Older Relative’s Medication Plan

CBD is often presented as a modest addition to a daily routine: a few drops, a capsule, a balm. For an older relative, however, no product sits in isolation. It joins a shelf of prescriptions, a care plan, a weekly pill organiser and, in some settings, a medication cabinet that staff alone can open. That context matters more than the gloss on the bottle.

This article is general information, not medical or legal advice. The central principle is straightforward: before CBD is offered to an older person, whether they live independently, with family or in a care home, the conversation should begin with their GP or pharmacist—not with a dropper.

Why older age changes the questions

Ageing affects how medicines are handled by the body, how easily side effects are noticed and how many products a person may already be taking. Polypharmacy—the use of several medicines at once—is common among older adults, and it makes any addition worth reviewing carefully.

CBD is not a licensed medicine in the UK. It is generally sold as a food supplement or consumer product, which means it does not arrive with the same prescribing checks as a prescription medicine. That does not make it automatically unsafe, but it does mean families should be cautious about assuming it is neutral. CBD can interact with some medicines, and the evidence base is still developing. A pharmacist can review the whole list, including prescribed medicines, over-the-counter products and supplements.

The first conversation: GP or pharmacist

Before sharing a bottle, ask whether the relative’s GP or pharmacist is aware of it. A medication review is the sensible starting point, particularly if the person takes medicines for epilepsy, blood pressure, heart conditions, pain, sleep or mood, or takes anticoagulants such as warfarin. The pharmacist does not need to endorse CBD for the question to be useful; they can flag possible interactions and note the product in the medication record.

Bring the actual product or a clear photograph of the label. A vague description such as “CBD oil” is not enough for a meaningful check. The pharmacist will want to know the stated CBD content, the carrier oil, any other ingredients, the recommended serving and how often the family intends it to be used.

Consent comes before convenience

An older relative is not a passive recipient of a family decision. If they have capacity, the choice is theirs. Capacity is decision-specific and time-specific: a person may be able to decide what to eat but not be able to weigh up a supplement alongside complex medicines. In England and Wales, the Mental Capacity Act 2005 provides the framework; Scotland and Northern Ireland have their own arrangements. Where capacity is uncertain, families should seek proper advice rather than proceed informally.

Consent should be explicit, recorded and revisitable. A person may agree to try a product and later change their mind. If someone lacks capacity, decisions should follow the relevant best-interests process, involving health and care professionals and, where appropriate, an attorney or advocate. A family member’s enthusiasm is not a substitute for that process.

Care homes are medication environments, not kitchen shelves

A care home is not simply a shared house with more support. It is a regulated setting with policies on medication administration, storage and record-keeping. Staff cannot generally accept an unlabelled bottle from a visitor and add it to a resident’s routine. Many homes require products to be authorised, recorded and stored securely; some will not administer food supplements or unlicensed products without a clear assessment.

Ask the care home manager what the policy is before bringing anything through the door. Useful questions include: who authorises a product; whether it can be kept in the resident’s room; whether staff will administer it; how it is recorded; and what happens if the resident refuses. Do not decant CBD into an unmarked bottle or add it to food without the care team’s knowledge. Covert administration is a serious issue and should never be a workaround.

Reading the label without making promises

CBD labels vary considerably. Look for the amount of CBD per millilitre and per bottle, not just a large number on the front. Check whether the product contains THC and at what level, what carrier oil is used, and whether there is a batch number and laboratory analysis. In the UK, CBD products sold as novel foods should appear on the Food Standards Agency’s public list; that listing is not a guarantee of effectiveness, but it is a useful verification step.

Be wary of labels that imply treatment for dementia, arthritis, anxiety or sleep problems. CBD is not licensed to treat those conditions, and a care home should not be asked to administer it on the strength of marketing language. The safer question is not “What will it cure?” but “What exactly is in it, who has reviewed it, and how will we know if it suits this person?”

A short checklist before the bottle is shared

Has the GP or pharmacist reviewed the relative’s full medicine list? Has consent been discussed and recorded? Does the care home—if involved—permit the product, and who will administer it? Is the label clear enough to identify CBD content, THC status and batch details? Is there a start date, a review date and a plan for noting any change in drowsiness, dizziness, appetite or confusion? If the answer to any of these is unclear, pause.

The calmest approach is not to treat CBD as a secret remedy or a family shortcut. It is to place it where it belongs: inside an ordinary, documented conversation about medicines, consent and care. That conversation may end with a decision not to use CBD at all—and that is a valid outcome. What matters is that the older person’s voice, and their clinical safety, come before the bottle.